Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic...
Nature Medicine - Analyses of clinical and genomic data from a cohort of 2,336 patients with pancreatic adenocarcinoma find that KRAS dosage gains are a hallmark of disease progression and are...
nature.com